Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | COASY | Q13057 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 2/20 | 0.39 |
| ▸ | LDHB | P07195 | 2/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205626 | 1.00 | ADORA3 (0.44) | ADORA3ADORA1ADORA2ADYRK1ACOASY | |
| SCHEMBL22270670 | 0.87 | DYRK1A (0.43) | ADORA3ADORA1ADORA2ADYRK1ACOASY | |
| SCHEMBL19205733 | 0.85 | ATP1A1 (0.44) | LDHALDHBP2RX3EGFRCDK1 | |
| SCHEMBL19205734 | 0.85 | ATP1A1 (0.44) | LDHALDHBP2RX3EGFRCDK1 | |
| SCHEMBL19205755 | 0.84 | LDHA (0.48) | LDHALDHBEGFR | |
| SCHEMBL18448954 | 0.84 | LDHA (0.48) | LDHALDHBEGFR | |
| SCHEMBL18484486 | 0.84 | LDHA (0.48) | LDHALDHBEGFR | |
| SCHEMBL19205739 | 0.83 | ALDH1A1 (0.46) | ADORA3ADORA1ADORA2ADYRK1ACOASY | |
| SCHEMBL18484150 | 0.78 | EGFR (0.45) | LDHALDHBPLK1P2RX3EGFR | |
| SCHEMBL18484149 | 0.78 | EGFR (0.45) | LDHALDHBPLK1P2RX3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| WO-2017021879-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | ADORA3 916/4885ADORA1 897/4885ADORA2A 1755/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | ADORA3 916/4885ADORA1 897/4885ADORA2A 1755/4885 |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ADORA3 826/4885ADORA1 818/4885ADORA2A 1726/4885 |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ADORA3 1968/4885ADORA1 1580/4885ADORA2A 2809/4885 |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ADORA3 826/4885ADORA1 818/4885ADORA2A 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.